Actelion Announces Multiple Presentations on Tracleer and the REVEAL Registry at CHEST 2007
CHICAGO, October 19, 2007 /PRNewswire/ -- Actelion Ltd today announced multiple presentations regarding Tracleer(R) (bosentan), including new Phase 3 data assessing the efficacy and safety of Tracleer in combination with sildenafil, and data obtained from the first 1,500 patients with pulmonary arterial hypertension (PAH) enrolled in the REVEAL(TM) (Registry to EValuate Early And Long-term PAH Disease Management) Registry. The presentations and publications are part of the proceedings at CHEST 2007, the annual meeting of the of Chest Physicians, being held October 20-25, 2007 at McCormick Place in Chicago, IL. The company will be exhibiting at booth # 239 in the Exhibit Hall.
The presentations and abstracts -- including date and location for each -- are as follows:
Tuesday, October 23, 2007, 12:30 p.m. - 2:00 p.m.
Session: Pulmonary Vascular Disease: Evaluation and Treatment, ID #858
Oral Presentation: REVEAL Registry: Baseline Characteristics of the First
Enrolled Patients
Location: Convention Center E264
Presenter: David Badesch, MD
Abstract #: 5982
Tuesday, October 23, 2007, 2:30 p.m. - 4:00 p.m.
Session: Pulmonary Vascular Disease: Pulmonary HTN, ID # 900
Oral Presentation: Bosentan improves hemodynamics in patients receiving
background Sildenafil treatment: results from EARLY, a randomized,
double-blind, placebo controlled study in patients with mildly
symptomatic pulmonary arterial hypertension
Location: Convention Center E266
Presenter: Lewis Rubin, MD
Abstract #: 5356
Session: Pulmonary Vascular Disease : Pulmonary HTN, ID # 900
Oral Presentation: Acute hemodynamic effect of Sildenafil in comparison
with inhaled nitric oxide in patients receiving Bosentan therapy for
pulmonary arterial hypertension (COMPASS-1)
Location: Convention Center E266
Presenter: Nazzareno Galie, MD
Abstract #: 5482
Wednesday, October 24, 2007, 12:30 p.m. - 2:00 p.m.
Session: Pulmonary Vascular Disease: Pulmonary HTN Evaluation and
Treatment, ID #893
Poster Presentation: REVEAL Registry: Treatment History and Treatment at
Baseline
Location: Convention Center, Exhibit Hall
Presenter: Michael McGoon, MD
Poster #: 585
Abstract #: 6023
Session: Pulmonary Vascular Disease: Pulmonary HTN Evaluation and
Treatment, ID #893
Poster Presentation: REVEAL Registry: Medical History and Time to
Diagnosis of Enrolled Patients
Location: Convention Center, Exhibit Hall
Presenter: C. Gregory Elliott, MD
Poster #: 584
Abstract #: 6036
Session: Pulmonary Vascular Disease: Pulmonary HTN Evaluation and
Treatment, ID #893
Poster Presentation: Goal-Directed Combination Therapy in Pulmonary
Arterial Hypertension (PAH): Study Design of COMPASS-3
Location: Convention Center, Exhibit Hall
Presenter: Fernando Torres, MD
Poster #: 573
Abstract #: 5963
About Tracleer(R) in Pulmonary Arterial Hypertension (PAH)
Tracleer(R) (bosentan), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hypertension (PAH) and made available by Actelion subsidiaries in the United States, the European Union, Japan, Australia, Canada, Switzerland and other markets worldwide.
Requires attention to two significant safety concerns: Potential for serious liver injury (including rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring) -- Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. High potential for major birth defects -- Pregnancy must be excluded and prevented by two forms of birth control; monthly pregnancy tests should be obtained. Because of these risks, Tracleer is only supplied through a controlled distribution.
About Actelion Pharmaceuticals
Actelion Pharmaceuticals has pioneered research and development in the pulmonary arterial hypertension (PAH) disease area. More than 40,000 PAH patients have been prescribed Actelion's product Tracleer(R) (bosentan), an orally available dual endothelin receptor antagonist for patients with World Health Organization (WHO) Class III or IV PAH. Tracleer was approved in 2001 as the first oral treatment for PAH, and is currently approved in the U.S., the European Union, and other markets worldwide. In January 2007, Actelion acquired CoTherix, Inc., whose product Ventavis(R) is approved and marketed in the United States for the treatment of patients with NYHA Class III or IV PAH.
CONTACT: Danielle Bertrand of WeissComm Partners, +1-415-946-1056,, for Actelion Dbertrand@wcpglobal.com
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Posted: October 2007
